热门资讯> 正文
Tarsus通过2亿美元融资承诺对现有债务进行再融资
2024-04-23 20:51
- Tarsus Pharmaceuticals (NASDAQ:TARS) secured $200M in committed capital from funds associated with Pharmakon Advisors, LP.
- Tarsus has elected to draw $75M on the closing date, April 19, 2024, with the remaining $125M of committed capital available at the company’s option in three tranches through specified time windows, the last ending in December 2025.
- Net proceeds to the company at closing will be approximately $40M.
- The new five-year interest-only credit facility with Pharmakon provides for three potential additional loan tranches, to be drawn at the company’s option, in principal amounts up to $25M, $50M and $50M, respectively, the latter two tranches available upon achievement of certain revenue thresholds.
- Source: Press Release
More on Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
- Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
- Tarsus Pharmaceuticals stock dips after pricing $100M securities offering
- Tarsus reports positive Phase 2 results for Lyme disease product
- Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
